Exparel (bupivacaine liposome) Injectable Suspension
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)
December 2015
WARNINGS AND PRECAUTIONS Specific for EXPAREL
Using EXPAREL followed by other bupivacaine formulations has not been...
Source: Drugs.com - Labeling Changes - Category: Drugs & Pharmacology Source Type: alerts
More News: Drugs & Pharmacology | Warnings